Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 41

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 41
---
          |

| (1) | Subject to Mr. Mack’s continued service through each applicable vesting date, the option awards will vest and become exercisable 25% on April 5, 2025, with the remaining balance vesting and becoming exercisable in substantially equal monthly installments over the next three years left in the service period. The option awards have been granted from the 2021 Inducement Plan. |

| (2) | Subject to Mr. Fuggetta’s continued service through each applicable vesting date, the option awards will vest and become exercisable 25% on March 21, 2025, with the remaining balance vesting and becoming exercisable in substantially equal monthly installments over the next three years left in the service period. The option awards have been granted from the 2022 Plan. |

| (3) | 25% of the option awards vested and became exercisable on March 23, 2024. Starting from April 23, 2024 the option awards started vesting in substantially equal monthly installments and will continue to vest on a monthly basis subject to Mr. Fuggetta’s continued service through each applicable vesting date until the end of the four-year vesting period. The option awards have been granted from the 2022 Plan. |

| (4) | 25% of the option awards vested and became exercisable on July 1, 2023. Starting from August 1, 2023 the option awards started vesting in substantially equal monthly installments and will continue to vest on a monthly basis subject to Mr. Fuggetta’s continued service through each applicable vesting date until the end of the four-year vesting period. The option awards have been granted from the 2022 Plan. |

| (5) | Upon Mr. Alder’s termination of employment with the Company effective as of June 25, 2024, a portion of his option awards were accelerated to vest and the remainder of the unvested option awards were forfeited. The option awards granted after 2021 were from the 2022 Plan and the options granted in 2021 were under the 2021 Inducement Plan. |

| (6) | The expiration date reflected herein is without regard to any events which may cause such option to expire earlier, such as termination of service. |

| (7) | Upon Mr. Alder’s termination of employment with the Company effective as of June 25,